<DOC>
	<DOCNO>NCT00289744</DOCNO>
	<brief_summary>The aim study evaluate long-term persistence hepatitis A B antibodies Years 6 , 7 , 8 , 9 10 subject receive first two dos primary vaccination schedule combine hepatitis A/hepatitis B vaccine . This protocol post deal objective &amp; outcome measure extension phase year 6 10 . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Long-Term Immune Persistence GSK Biologicals ' Combined Hepatitis A &amp; B Vaccine Injected According 0,6 Month Schedule</brief_title>
	<detailed_description>To evaluate long-term antibody persistence , volunteer bleed Years 6 , 7 , 8 , 9 10 first vaccine dose primary vaccination course determine anti-HAV anti-HBs antibody concentration . If subject become seronegative anti-HAV antibody lose anti-HBs seroprotection concentration long-term blood sampling time point ( i.e . Years 6 , 7 , 8 , 9 10 ) , he/ offer additional vaccine dose .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects participate study participate primary study combine hepatitis A/ hepatitis B vaccine . Written inform consent obtain subject and/ parent guardian subject blood sample visit year .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>TWINRIXâ„¢ ADULT</keyword>
	<keyword>Hepatitis A</keyword>
</DOC>